{
    "nctId": "NCT06188494",
    "briefTitle": "UNFOLD Study Egypt",
    "officialTitle": "A Multicenter, Observational, Secondary Data Collection, Retrospective, National Study to Assess the Prevalence of HER2-low Breast Cancer Among Patients Previously Diagnosed With Unresectable and/or Metastatic HER2-Negative Breast Cancer in Egypt - UNFOLD",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "HER2-low prevalence",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Men or women \u2265 18 years of age,\n2. Must have a histological, cytological, or radiological confirmed diagnosis of unresectable or/and mBC between 01 January 2017 and 31 December 2020, with at least 2 years of follow-up data unless patient's death is confirmed,\n3. Diagnosed as HER2-neg (HER2 IHC 0, 1+, 2+/ISH-), regardless of hormone status,\n4. Must have a report in her file with HER2 scoring with IHC/ISH or both,\n5. Progressed on any systemic anti-cancer therapy (eg, ET, chemotherapy, CDK4/6i, targeted therapies other than anti-HER2, or immunotherapy) in the metastatic setting.\n6. Due to the retrospective nature of the study a waiver grant of the consent will be requested from the IRB/IEC for the study participants, if waiver not granted Patient or next of kin/legal representative (for deceased patients at study entry) willing and able to provide written informed consent according to the local regulations.\n\nExclusion Criteria:\n\n* Records of patients who meet any of the following criteria will be excluded:\n\n  1. History of other malignancies than mBC,\n  2. Historical HER2 status of IHC 2+/ISH+ or 3+, or HER2 amplified.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}